Skip to main content
Top
Published in: BMC Ophthalmology 1/2018

Open Access 01-12-2018 | Research article

The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units

Authors: Yunxia Leng, Wenzhi Huang, Guoliang Ren, Cheng Cai, Qingbiao Tan, Yuqin Liang, Weizhong Yang, Zongyin Gao

Published in: BMC Ophthalmology | Issue 1/2018

Login to get access

Abstract

Background

Retinopathy of prematurity (ROP) is a vascular proliferative disorder of the developing retina and a significant cause of childhood blindness around the world. The incidence of ROP is affected by many factors, and the incidence rate varies from country to country. The purpose of this study is to report the incidence and risk factors of ROP in neonatal intensive care unit (NICU) of Guangzhou First People’s Hospital in China.

Methods

A retrospective review was performed on 436 premature infants who were consecutive ROP screened in the NICU of Guangzhou First People’s Hospital from March 2013 to October 2017. The single-factor analysis and the logistic multivariate regression analysis were used to detect risk factors of ROP.

Results

Total 436 premature infants were consecutive ROP screened, 138 (31.65%) were found ROP, and 61(13.99%) were treated. The single-factor analysis revealed that the incidence of ROP was associated with multiple births, gestational age, birth weight, mechanical ventilation, intravascular hemolysis, the number of operations and blood culture results. The logistic multivariate regression analysis revealed that gestational age; birth weight, mechanical ventilation, minimum SaO2 and daily weight gain were independent risk factors for ROP onset. Forty-nine patients underwent retinal laser photocoagulation with recurrence 20 patients. Twelve patients underwent anti-VEGF drug (Ranibizumab) via intraocular injection with 5 patients of recurrence.

Conclusions

The incidence of ROP in NICU of Guangzhou China will match those in middle-income countries, but higher than high-income countries. Anti-VEGF drugs could be preferred as a good treatment method for zone 1 ROP and aggressive posterior ROP.
Literature
1.
go back to reference Castro Conde JR, et al. Retinopathy of prematurity. Prevention, screening and treatment guidelines. An Pediatr (Barc). 2009;71(6):514–23.CrossRef Castro Conde JR, et al. Retinopathy of prematurity. Prevention, screening and treatment guidelines. An Pediatr (Barc). 2009;71(6):514–23.CrossRef
2.
go back to reference Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2013;368(12):1162–3.PubMed Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2013;368(12):1162–3.PubMed
3.
go back to reference Jasani B, Nanavati R, Kabra N. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2013;368(12):1161–2.CrossRef Jasani B, Nanavati R, Kabra N. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2013;368(12):1161–2.CrossRef
4.
go back to reference Rao RC, Dlouhy BJ. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2013;368(12):1161.CrossRef Rao RC, Dlouhy BJ. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2013;368(12):1161.CrossRef
5.
go back to reference Celebi AR, et al. The incidence and risk factors of severe retinopathy of prematurity in extremely low birth weight infants in Turkey. Med Sci Monit. 2014;20:1647–53.CrossRef Celebi AR, et al. The incidence and risk factors of severe retinopathy of prematurity in extremely low birth weight infants in Turkey. Med Sci Monit. 2014;20:1647–53.CrossRef
6.
go back to reference Sukgen EA, Kocluk Y. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol. 2017;80(1):30–4.CrossRef Sukgen EA, Kocluk Y. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol. 2017;80(1):30–4.CrossRef
7.
go back to reference Lundgren P, et al. Aggressive posterior retinopathy of prematurity is associated with multiple infectious episodes and thrombocytopenia. Neonatology. 2017;111(1):79–85.CrossRef Lundgren P, et al. Aggressive posterior retinopathy of prematurity is associated with multiple infectious episodes and thrombocytopenia. Neonatology. 2017;111(1):79–85.CrossRef
8.
go back to reference Lundgren P, et al. Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity. Acta Paediatr. 2018;107(5):759–66.CrossRef Lundgren P, et al. Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity. Acta Paediatr. 2018;107(5):759–66.CrossRef
9.
go back to reference Group., C.M.A.o. Screening guide for retinopathy of premature infants in China. Chin J OphthaImoI. 2014;50(0412–4081.2014.12.017):933–5. Group., C.M.A.o. Screening guide for retinopathy of premature infants in China. Chin J OphthaImoI. 2014;50(0412–4081.2014.12.017):933–5.
10.
go back to reference International Committee for the Classification of Retinopathy of, P. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991–9.CrossRef International Committee for the Classification of Retinopathy of, P. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991–9.CrossRef
11.
go back to reference Gilbert C, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115(5):e518–25.CrossRef Gilbert C, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115(5):e518–25.CrossRef
12.
go back to reference Gilbert C, et al. Retinopathy of prematurity in middle-income countries. Lancet. 1997;350(9070):12–4.CrossRef Gilbert C, et al. Retinopathy of prematurity in middle-income countries. Lancet. 1997;350(9070):12–4.CrossRef
13.
go back to reference Skalet AH, et al. Telemedicine screening for retinopathy of prematurity in developing countries using digital retinal images: a feasibility project. J AAPOS. 2008;12(3):252–8.CrossRef Skalet AH, et al. Telemedicine screening for retinopathy of prematurity in developing countries using digital retinal images: a feasibility project. J AAPOS. 2008;12(3):252–8.CrossRef
14.
go back to reference Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77–82.CrossRef Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77–82.CrossRef
15.
go back to reference King MJ. Retrolental fibroplasia; a clinical study of 238 cases. Arch Ophthal. 1950;43(4):694–711.CrossRef King MJ. Retrolental fibroplasia; a clinical study of 238 cases. Arch Ophthal. 1950;43(4):694–711.CrossRef
16.
go back to reference Clemett R, Darlow B. Results of screening low-birth-weight infants for retinopathy of prematurity. Curr Opin Ophthalmol. 1999;10(3):155–63.CrossRef Clemett R, Darlow B. Results of screening low-birth-weight infants for retinopathy of prematurity. Curr Opin Ophthalmol. 1999;10(3):155–63.CrossRef
17.
go back to reference Lee SK, et al. Evidence for changing guidelines for routine screening for retinopathy of prematurity. Arch Pediatr Adolesc Med. 2001;155(3):387–95.CrossRef Lee SK, et al. Evidence for changing guidelines for routine screening for retinopathy of prematurity. Arch Pediatr Adolesc Med. 2001;155(3):387–95.CrossRef
18.
go back to reference Trinavarat A, Atchaneeyasakul LO, Udompunturak S. Applicability of American and British criteria for screening of the retinopathy of prematurity in Thailand. Jpn J Ophthalmol. 2004;48(1):50–3.CrossRef Trinavarat A, Atchaneeyasakul LO, Udompunturak S. Applicability of American and British criteria for screening of the retinopathy of prematurity in Thailand. Jpn J Ophthalmol. 2004;48(1):50–3.CrossRef
19.
go back to reference Astasheva IB, Sidorenko EI. Fulminant retinopathy of prematurity (“plus-disease”): incidence, risk factors, diagnostic criteria, and variations in course. Vestn oftalmol. 2002;118(6):5–9.PubMed Astasheva IB, Sidorenko EI. Fulminant retinopathy of prematurity (“plus-disease”): incidence, risk factors, diagnostic criteria, and variations in course. Vestn oftalmol. 2002;118(6):5–9.PubMed
20.
go back to reference Chen Y, Li X. Characteristics of severe retinopathy of prematurity patients in China: a repeat of the first epidemic? Br J Ophthalmol. 2006;90(3):268–71.CrossRef Chen Y, Li X. Characteristics of severe retinopathy of prematurity patients in China: a repeat of the first epidemic? Br J Ophthalmol. 2006;90(3):268–71.CrossRef
21.
go back to reference Dutta S, et al. Risk factors of threshold retinopathy of prematurity. Indian Pediatr. 2004;41(7):665–71.PubMed Dutta S, et al. Risk factors of threshold retinopathy of prematurity. Indian Pediatr. 2004;41(7):665–71.PubMed
22.
go back to reference Varughese S, et al. Magnitude of the problem of retinopathy of prematurity. Experience in a large maternity unit with a medium size level-3 nursery. Indian J Ophthalmol. 2001;49(3):187–8.PubMed Varughese S, et al. Magnitude of the problem of retinopathy of prematurity. Experience in a large maternity unit with a medium size level-3 nursery. Indian J Ophthalmol. 2001;49(3):187–8.PubMed
23.
go back to reference Zhaoliang H. Review and recognition on urban size of Beijing. J Urban Reg Plann. 2011;2:18. Zhaoliang H. Review and recognition on urban size of Beijing. J Urban Reg Plann. 2011;2:18.
24.
go back to reference Xu Y, et al. Screening for retinopathy of prematurity in China: a neonatal units-based prospective study. Invest Ophthalmol Vis Sci. 2013;54(13):8229–36.CrossRef Xu Y, et al. Screening for retinopathy of prematurity in China: a neonatal units-based prospective study. Invest Ophthalmol Vis Sci. 2013;54(13):8229–36.CrossRef
25.
go back to reference Jin J, et al. Analysis on the result of retinopathy of prematurity screening in 1225 premature infants. Zhonghua Er Ke Za Zhi. 2010;48(11):829–33.PubMed Jin J, et al. Analysis on the result of retinopathy of prematurity screening in 1225 premature infants. Zhonghua Er Ke Za Zhi. 2010;48(11):829–33.PubMed
26.
go back to reference Chen Y, et al. Risk factors for retinopathy of prematurity in six neonatal intensive care units in Beijing. China Br J Ophthalmol. 2008;92(3):326–30.CrossRef Chen Y, et al. Risk factors for retinopathy of prematurity in six neonatal intensive care units in Beijing. China Br J Ophthalmol. 2008;92(3):326–30.CrossRef
27.
go back to reference Chen Y, et al. Analysis of changes in characteristics of severe retinopathy of prematurity patients after screening guidelines were issued in China. Retina. 2015;35(8):1674–9.CrossRef Chen Y, et al. Analysis of changes in characteristics of severe retinopathy of prematurity patients after screening guidelines were issued in China. Retina. 2015;35(8):1674–9.CrossRef
28.
go back to reference Shao XM Y, Qiu XS. Retionopathy of prematurity. Practicalneonatology. 4th ed. Beijing: People’s Medical Publishing House; 2011. p. 887–92. Shao XM Y, Qiu XS. Retionopathy of prematurity. Practicalneonatology. 4th ed. Beijing: People’s Medical Publishing House; 2011. p. 887–92.
29.
go back to reference Ma Xue-ren ZQ, Hong K, Xue-Ping LI, Zhen-Juan Z, Juan W. Screening results and risk factors of 310 cases of retinopathy of prematurity in Qinghai Province. Chinese J Fundus Dis. 2017;33:631–2. Ma Xue-ren ZQ, Hong K, Xue-Ping LI, Zhen-Juan Z, Juan W. Screening results and risk factors of 310 cases of retinopathy of prematurity in Qinghai Province. Chinese J Fundus Dis. 2017;33:631–2.
30.
go back to reference Varughese S, et al. Retinopathy of prematurity in South Africa: an assessment of needs, resources and requirements for screening programmes. Br J Ophthalmol. 2008;92(7):879–82.CrossRef Varughese S, et al. Retinopathy of prematurity in South Africa: an assessment of needs, resources and requirements for screening programmes. Br J Ophthalmol. 2008;92(7):879–82.CrossRef
31.
go back to reference Onyango O, et al. Retinopathy of prematurity in Kenya: prevalence and risk factors in a hospital with advanced neonatal care. Pan Afr Med J. 2018;29:152.CrossRef Onyango O, et al. Retinopathy of prematurity in Kenya: prevalence and risk factors in a hospital with advanced neonatal care. Pan Afr Med J. 2018;29:152.CrossRef
32.
go back to reference Gerull R, et al. Incidence of retinopathy of prematurity (ROP) and ROP treatment in Switzerland 2006-2015: a population-based analysis. Arch Dis Child Fetal Neonatal Ed. 2018;103(4):F337–42.CrossRef Gerull R, et al. Incidence of retinopathy of prematurity (ROP) and ROP treatment in Switzerland 2006-2015: a population-based analysis. Arch Dis Child Fetal Neonatal Ed. 2018;103(4):F337–42.CrossRef
33.
go back to reference Holmstrom G, et al. Increased frequency of retinopathy of prematurity over the last decade and significant regional differences. Acta Ophthalmol. 2018;96(2):142–8.CrossRef Holmstrom G, et al. Increased frequency of retinopathy of prematurity over the last decade and significant regional differences. Acta Ophthalmol. 2018;96(2):142–8.CrossRef
34.
35.
go back to reference Ludwig CA, et al. The epidemiology of retinopathy of prematurity in the United States. Ophthalmic Surg Lasers Imaging Retina. 2017;48(7):553–62.CrossRef Ludwig CA, et al. The epidemiology of retinopathy of prematurity in the United States. Ophthalmic Surg Lasers Imaging Retina. 2017;48(7):553–62.CrossRef
36.
go back to reference Ugurbas SC, et al. Comparison of UK and US screening criteria for detection of retinopathy of prematurity in a developing nation. J AAPOS. 2010;14(6):506–10.CrossRef Ugurbas SC, et al. Comparison of UK and US screening criteria for detection of retinopathy of prematurity in a developing nation. J AAPOS. 2010;14(6):506–10.CrossRef
37.
go back to reference Hard AL, Smith LE, Hellstrom A. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal Neonatal Med. 2013;S1744-165X(13)00007-3. Hard AL, Smith LE, Hellstrom A. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal Neonatal Med. 2013;S1744-165X(13)00007-3.
38.
go back to reference Can E, et al. Early aggressive parenteral nutrition induced high insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP3) levels can prevent risk of retinopathy of prematurity. Iran J Pediatr. 2013;23(4):403–10.PubMedPubMedCentral Can E, et al. Early aggressive parenteral nutrition induced high insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP3) levels can prevent risk of retinopathy of prematurity. Iran J Pediatr. 2013;23(4):403–10.PubMedPubMedCentral
39.
go back to reference Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515–26.CrossRef Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515–26.CrossRef
40.
go back to reference Feng J, et al. Vascular endothelial growth factor and apelin in plasma of patients with retinopathy of prematurity. Acta Ophthalmol. 2017;95(6):e514–5.CrossRef Feng J, et al. Vascular endothelial growth factor and apelin in plasma of patients with retinopathy of prematurity. Acta Ophthalmol. 2017;95(6):e514–5.CrossRef
41.
go back to reference VanderVeen DK, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of ophthalmology. Ophthalmology. 2017;124(5):619–33.CrossRef VanderVeen DK, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of ophthalmology. Ophthalmology. 2017;124(5):619–33.CrossRef
42.
go back to reference Fernandez MP, et al. Histopathologic characterization of the expression of vascular endothelial growth factor in a case of retinopathy of prematurity treated with Ranibizumab. Am J Ophthalmol. 2017;176:134–40.CrossRef Fernandez MP, et al. Histopathologic characterization of the expression of vascular endothelial growth factor in a case of retinopathy of prematurity treated with Ranibizumab. Am J Ophthalmol. 2017;176:134–40.CrossRef
43.
go back to reference Chuang LJ, et al. A modified developmental care bundle reduces pain and stress in preterm infants undergoing examinations for retinopathy of prematurity (ROP): a randomized controlled trial. J Clin Nurs. 2018. Chuang LJ, et al. A modified developmental care bundle reduces pain and stress in preterm infants undergoing examinations for retinopathy of prematurity (ROP): a randomized controlled trial. J Clin Nurs. 2018.
44.
go back to reference Kabatas EU, et al. Comparison of intravitreal bevacizumab, intravitreal Ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res. 2017;42(7):1054–8.CrossRef Kabatas EU, et al. Comparison of intravitreal bevacizumab, intravitreal Ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res. 2017;42(7):1054–8.CrossRef
45.
go back to reference Mota A, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol. 2012;3(1):136–41.CrossRef Mota A, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol. 2012;3(1):136–41.CrossRef
46.
go back to reference Gotz-Wieckowska A, et al. Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment. Sci Rep. 2017;7(1):11894.CrossRef Gotz-Wieckowska A, et al. Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment. Sci Rep. 2017;7(1):11894.CrossRef
47.
go back to reference Zhao M, et al. Expression of Total vascular endothelial growth factor and the anti-angiogenic VEGF 165 b isoform in the vitreous of patients with retinopathy of prematurity. Chin Med J. 2015;128(18):2505–9.CrossRef Zhao M, et al. Expression of Total vascular endothelial growth factor and the anti-angiogenic VEGF 165 b isoform in the vitreous of patients with retinopathy of prematurity. Chin Med J. 2015;128(18):2505–9.CrossRef
48.
go back to reference Sonmez K, et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology. 2008;115(6):1065–70 e1.CrossRef Sonmez K, et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology. 2008;115(6):1065–70 e1.CrossRef
49.
go back to reference Raizada S, Kandari JA, Sabti KA. Will the BEAT-ROP study results really beat ROP? Invest Ophthalmol Vis Sci. 2011;52(12):9288–9.CrossRef Raizada S, Kandari JA, Sabti KA. Will the BEAT-ROP study results really beat ROP? Invest Ophthalmol Vis Sci. 2011;52(12):9288–9.CrossRef
50.
go back to reference Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 2011;118(7):1227–8.PubMed Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 2011;118(7):1227–8.PubMed
51.
go back to reference Wallace DK. Retinopathy of prematurity: anti-VEGF treatment for ROP: which drug and what dose? J AAPOS. 2016;20(6):476–8.CrossRef Wallace DK. Retinopathy of prematurity: anti-VEGF treatment for ROP: which drug and what dose? J AAPOS. 2016;20(6):476–8.CrossRef
52.
go back to reference Gonzalez Viejo I, Ferrer Novella C, Pueyo Royo V. Use of anti-VEGF (anti-vascular endothelial growth factor) in retinopathy of prematurity (ROP). Arch Soc Esp Oftalmol. 2011;86(7):207–8.CrossRef Gonzalez Viejo I, Ferrer Novella C, Pueyo Royo V. Use of anti-VEGF (anti-vascular endothelial growth factor) in retinopathy of prematurity (ROP). Arch Soc Esp Oftalmol. 2011;86(7):207–8.CrossRef
53.
go back to reference Wu WC, et al. Serum vascular endothelial growth factor after bevacizumab or Ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37(4):694–701.CrossRef Wu WC, et al. Serum vascular endothelial growth factor after bevacizumab or Ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37(4):694–701.CrossRef
54.
go back to reference Shah N, Gupta MP, Chan RVP. Persistent angiographic abnormalities after intravitreal anti-vascular endothelial growth factor therapy for retinopathy of prematurity. JAMA Ophthalmol. 2018;136(4):436-7.CrossRef Shah N, Gupta MP, Chan RVP. Persistent angiographic abnormalities after intravitreal anti-vascular endothelial growth factor therapy for retinopathy of prematurity. JAMA Ophthalmol. 2018;136(4):436-7.CrossRef
55.
go back to reference Kandasamy Y, et al. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review. Br J Ophthalmol. 2017;101(1):21–4.CrossRef Kandasamy Y, et al. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: a systematic review. Br J Ophthalmol. 2017;101(1):21–4.CrossRef
56.
go back to reference Gunay M, et al. Comparison of bevacizumab, Ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462–9.CrossRef Gunay M, et al. Comparison of bevacizumab, Ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462–9.CrossRef
57.
go back to reference Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35(4):675–80.CrossRef Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35(4):675–80.CrossRef
Metadata
Title
The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units
Authors
Yunxia Leng
Wenzhi Huang
Guoliang Ren
Cheng Cai
Qingbiao Tan
Yuqin Liang
Weizhong Yang
Zongyin Gao
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2018
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-018-0973-1

Other articles of this Issue 1/2018

BMC Ophthalmology 1/2018 Go to the issue